Marburg virus disease

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

“…The first outbreak of MARV occurred in 1967 in Marburg, Germany, following exposure to monkeys imported from Uganda. This was followed almost 10 years later in 1976 by the first recognized outbreak of EBOV in the country Democratic Republic of the Congo, formerly known as Zaire [3][4][5]. The natural hosts of EBOV and MARV are unknown, although human cases occur most often due to contact with infected monkeys, humans, or their blood and tissues [4][5][6].…”

“…This was followed almost 10 years later in 1976 by the first recognized outbreak of EBOV in the country Democratic Republic of the Congo, formerly known as Zaire [3][4][5]. The natural hosts of EBOV and MARV are unknown, although human cases occur most often due to contact with infected monkeys, humans, or their blood and tissues [4][5][6]. Natural outbreaks have been on the rise recently, most likely not only due in part to improved surveillance, but also due to more frequent contact between monkeys and humans because of the destruction of natural habitats in Africa (http://www.who.int/disease-outbreaknews/disease/bydisease.htm).…”

Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses

“…Marburg virus (MBG) is a 'Biosafety Level 4' agent (Richardson & Barkley, 1988) that was first identified in 1967 following human outbreaks of acute haemorrhagic fever in the cities of Marburg and Frankfurt, Germany, and Belgrade, Yugoslavia (Martini & Siegert, 1971). Initial infections occurred in persons working with blood, organs or cell culturing of tissues from infected African green monkeys (Cercopithecus aethiops) imported from Uganda.…”

Aerosol Exposure to the Angola Strain of Marburg Virus Causes Lethal Viral Hemorrhagic Fever in Cynomolgus Macaques

“…These and other clinical features of human infections have been described in a number of reports. 9,15,17,57 A delicate temporally associated balance between the development of a protective immune response and a deleterious inflammatory response appears critical to determining the outcome of infection. For example, patients who recover from EBOV-Zaire infection develop an early immune response involving specific humoral factors and a tightly regulated cytotoxic T-lymphocyte response.…”